You are here: Home » Companies » Results
Business Standard

Jubilant Life Sciences Sept quarter net profit declines 10% to Rs 224 crore

Drug firm Jubilant Life Sciences on Wednesday reported a 10.13% decline in its consolidated net profit to Rs 224.12 crore for the quarter ended September,mainly on account of higher taxes

Jubilant Life Sciences | Q2 results

Press Trust of India  |  New Delhi 

cash, currency, notes, funds, investment, shares, growth, profit, loss, tax, money, income, earnings

Drug firm on Wednesday reported a 10.13 per centdecline in its consolidated net profit to Rs 224.12 crore for the quarter ended September,mainly on account of higher taxes.

The company had posted a net profit of Rs 249.39 crore for the correspondingperiod of the previous fiscal, said in a BSE filing.

Total revenue from operations stood at Rs 2,374.89 crore for the quarter under consideration. It was Rs 2,265.93 crore for the same period a year ago, it added.

Tax expense of the company for the quarter was Rs 89.55 crore as against Rs 42.84 crore for the same period of the previous fiscal, the filing said.

"Q2'FY21 has witnessed a substantial improvement over the previous quarter despite continued adverse impact of the COVID-19 pandemic in at least the first half of Q2,"Jubilant Life SciencesChairmanShyam S Bhartia andCo-Chairman & MD Hari S Bhartia said.

With the strong demand recovery and new business sign-ups, "we expect strong performance in our Pharma, Life Science Ingredients (LSI) and Drug Discovery & Development Solutions (DDDS) businesses in the H2'FY21," they added.

Shares ofJubilant Life Sciences closed at Rs706.70per scrip on BSE, up 1.50 per cent over previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 04 2020. 17:16 IST